Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CAR Ts approved for new technology add-on payments

CMS approved new technology add-on payments (NTAPs) for CAR T cell therapies Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) and Yescarta axicabtagene ciloleucel from the Kite Pharma

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE